Liposomal Amphotericin B and Isavuconazole/Posaconazole in Br-IFD（ Breakthrough Invasive Fungal Disease） in Patients With Malignant Hematological Diseases

Inclusion Criteria: * Male or female patients aged ≥ 18 years at the beginning of treatment. * The patient or their guardian must be able to understand and sign a written informed consent form (which must be obtained before starting any research procedure) * Blood based diseases, mainly AML( Acute Myeloid Leukemia), ALL(Acute Lymphoblastic Leukemia), MDS(Myelodysplastic Syndromes) * Breakthrough invasive fungal disease occurs after receiving antifungal prophylaxis with triazole drugs for ≥ 7 days * According to the latest definition of MSGERC, breakthrough IFD is defined as any IFD that occurs during exposure to antifungal drugs, including fungal infections outside the spectrum of antifungal activity * Proven, probable, and possible IFD in accordance with the\< The Chinese guidelines for the diagnosis and treatment of invasive fungal disease in patients with hematological disorders and cancers (the 6th revision) \> Exclusion Criteria: * Confirmed patients with allergies/rapid onset severe allergic reactions/intolerance to L-AmB or isavuconazole /posaconazole * Serum creatinine level ≥ 2 times the upper limit of normal * The level of transaminase or alkaline phosphatase is ≥ 5 times the normal upper limit, and bilirubin is ≥ 3 times the normal upper limit * Patients who are breastfeeding * Pregnant patients * Expected life expectancy is less than 30 days * Patients deemed ineligible by the investigator due to medical, ethical, or logistical reasons.